Related Experiment Videos
Vascular endothelial growth factor (VEGF) expression in plasmacytoma
Semra Paydas1, Suzan Zorludemir, Fikri Baslamisli
1Department of Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey. sepay@mail.cu.edu.tr
Leukemia & Lymphoma
|March 23, 2002
Summary
Vascular endothelial growth factor (VEGF) was found in two-thirds of plasmacytoma cases, particularly those with immature cell morphology. This suggests a link between VEGF expression and plasmacytoma characteristics.
Area of Science:
- Oncology
- Hematology
- Molecular Biology
Background:
- Vascular endothelial growth factor (VEGF) is crucial for angiogenesis in solid tumors.
- Its role in hematologic malignancies, like plasmacytoma, is less understood.
- Plasmacytoma (Pm) is a plasma cell neoplasm with varying clinical behavior.
Purpose of the Study:
- To investigate VEGF expression in plasmacytoma.
- To correlate VEGF expression with histopathologic grade (mature vs. immature morphology).
Main Methods:
- Analyzed 47 plasmacytoma samples (33 bone, 14 soft tissue).
- Assessed VEGF expression using immunohistochemical analysis.
- Scored VEGF expression based on the percentage of stained cells.
- Compared VEGF expression with histopathologic morphology (mature/immature).
Main Results:
- VEGF expression was detected in 32 out of 47 (approximately 68%) plasmacytoma cases.
- Strong VEGF expression was predominantly observed in immature morphology samples.
- A statistically significant association was found between immature morphology and VEGF expression (p < 0.0264).
Conclusions:
- VEGF is expressed in a significant proportion of plasmacytomas.
- VEGF expression is significantly associated with immature histopathologic morphology.
- Further research is needed to clarify the clinical implications of VEGF in plasmacytoma, including microvasculature and progression risk.